Conclusions: The Lrp6 function affects individual susceptibility to NAFLD and the therapeutic effect of silibinin through the Wnt/β-catenin-Cyp2e1 signaling pathway. This evidence concerns the gene CYP2E1 and metabolic dysfunction-associated steatotic liver disease.